Johnson and Johnson announced that it has entered into an agreement to acquire Momenta Pharmaceuticals, Inc. for $6.5 billion.  The acquisition gives J&J’s Janssen unit full global rights to Momenta’s nipocalimab (M281), an anti-FcRn antibody designed to treat a number of autoantibody-driven disorders, including generalized myasthenia gravis (gMG), warm autoimmune hemolytic anemia (wAIHA), and hemolytic disease of the fetus and newborn (HDFN). Janssen will also acquire Momenta’s pipeline of clinical and pre-clinical assets. We have previously reported that although Momenta discontinued much of its biosimilars program, Momenta remains committed to its biosimilar of aflibercept (M710).